Agios Pharmaceuticals reported a net loss of $112.0 million in Q2 2025, an increase from $96.1 million in Q2 2024. Despite the loss, the company saw a significant increase in PYRUKYND net product revenue, reaching $12.5 million, up from $8.6 million in the prior year. The company ended the quarter with $1.3 billion in cash, cash equivalents, and marketable securities.
PYRUKYND net product revenue increased to $12.5 million in Q2 2025, up from $8.6 million in Q2 2024.
The company reported a net loss of $112.0 million for the second quarter of 2025.
Agios ended the second quarter with $1.3 billion in cash, cash equivalents, and marketable securities.
The sNDA for PYRUKYND in thalassemia is under active FDA review with a PDUFA goal date of September 7, 2025.
Agios is focused on the potential U.S. approval of PYRUKYND for thalassemia and expects topline results from the RISE UP Phase 3 trial for PYRUKYND in sickle cell disease by year-end, with a potential U.S. commercial launch in 2026. The company also initiated a Phase 2 trial for tebapivat in sickle cell disease and received IND clearance for AG-236.
Analyze how earnings announcements historically affect stock price performance